May 14, 2014

Mylan on Wednesday announced that it has launched olanzapine orally disintegrating tablets in 5-mg, 10-mg, 15-mg and 20-mg strengths. The drug is the generic version of Zyprexa Zydis tablets from Eli Lilly and Co.

May 13, 2014

Valeant Pharmaceuticals on Monday announced that certain of its subsidiaries have entered into settlement agreements with Actavis related to Actavis' generic versions of Tiazac XC.

May 12, 2014

Actavis on Monday announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%.

May 9, 2014

Ajanta Pharma USA on Friday announced the launch of risperidone tablets (0.25-mg, 0.5-mg, 1-mg, 2-mg, 3-mg and 4-mg), the generic version of Risperdal.

May 9, 2014

Bayer agreed to acquire the consumer care business of U.S. pharmaceutical company Merck for a purchase price of $14.2 billion. The OTC acquisition will give Bayer the global No. 2 position in nonprescription products following recently announced consolidations in this growing healthcare industry segment, and will significantly enhance Bayer’s business across multiple therapeutic categories and geographies. Merck's consumer care business includes such leading brands as Claritin, Coppertone and Dr. Scholl’s. Pro forma sales of the combined businesses in 2013 amounted to $7.4 billion with Merck’s business contributing approximately $2.2 billion.

Upon completion of the acquisition, Bayer is expected to achieve global leadership positions in dermatology and gastrointestinals and advance to the No. 2 position in the cold, allergy, sinus and flu category. Bayer will remain No. 2 in nutritionals and No. 3 in analgesics. Overall, the proposed GlaxoSmithKline-Novartis combination represents the largest consumer health business with about 5.7% share, according to reports. The Bayer/Merck combination comes in second with around 4.5% share. McNeil Consumer rounds out the top three globally with a share just above 4%.

May 9, 2014

CorePharma on Thursday announced the launch of methylphenidate hydrochloride tablets USP, the generic version of Ritalin from Novartis.

May 9, 2014

Enaltus recently announced three new additions to its line of ScarAway scar removal products.

May 8, 2014

Actavis announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS (clonidine transdermal system, USP, 0.1-mg/day, 0.2-mg/day, and 0.3-mg/day for one week).

May 8, 2014

Although some guidelines recommend lipid screening for children and adolescents of certain ages, data indicate that only about 3% are having their cholesterol tested during health visits, according to a study in the May 7 issue of JAMA, a theme issue on child health.

May 7, 2014

M&M Products Co. has expanded its Nothing But product line with the recent debut of Nothing But’s Melted Shea Butter Leave-In Conditioner.

May 7, 2014

Mitchum has expanded its portfolio with the 2014 launch of Mitchum Clinical, the brand’s only soft solid with the odor-fighting benefits of oxygen odor-control technology.

May 6, 2014

AstraZeneca on Tuesday announced the Food and Drug Administration approved Epanova (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

May 6, 2014

Axium Healthcare Pharmacy on Tuesday announced that it has been accepted into the GlaxoSmithKline Oncology network.

May 6, 2014

In a related transaction to Tuesday morning's acquisition of Merck's OTC portfolio, Bayer also agreed to enter into a strategic pharma collaboration in the area of cardiovascular diseases with a focus on sGC modulation.

May 6, 2014

Coca-Cola on Monday announced that it's eliminating brominated vegetable oil in its products after consumers reached out to express their objections to the ingredient, according to a report from the New York Times.

May 6, 2014

Pfizer's Nexium 24HR will launch May 27, Pfizer reported in a conference call Monday.

May 2, 2014

An average of $3.9 billion per year in avoidable healthcare utilization costs would be realized if all U.S. adults older than 55 years diagnosed with age-related eye disease were to use lutein and zeaxanthin dietary supplements at preventive intake levels, according to a new economic report released Thursday by the Council for Responsible Nutrition.

May 1, 2014

Purdue Pharma on Wednesday announced that it filed a new drug application with the Food and Drug Administration to market a hydrocodone bitartrate tablet, which is formulated to incorporate abuse-deterrent technology.

April 30, 2014

The Food and Drug Administration on Tuesday granted approval to Zykadia (ceritinib) for patients with a specific type of late-stage (metastatic) non-small cell lung cancer (NSCLC).

April 29, 2014

Jubilant Life Sciences, an integrated pharmaceuticals and life sciences company, last week announced that it received approval from the Food and Drug Administration for spironolactone tablets, 25 mg, 50 mg and 100 mg, which is the generic version of Aldactone.

April 28, 2014

Sandoz on Monday announced the introduction of its adapalene 0.3% gel, a generic version of Differin gel, 0.3% from Galderma Labs.

April 24, 2014

Good news: you won’t need to remind your kids to take their daily vitamins, they’ll be reminding you! Angry Birds™ Vitamin Chews include 21 vitamins and minerals to support healthy eyes and strong bones along with a healthy immune system. These tasty vitamins are naturally flavored and sweetened and include fruit and vegetable extracts.

April 24, 2014

A cough syrup produced by Actavis will no longer be available due to the negative light cast on the product stemming from abuse by musicians like Justin Bieber and Soulja Boy, according to a report from the Huffington Post.

April 23, 2014

Bayer HealthCare on Tuesday announced that the Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for Bayer's investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis.